MicroLactin Ingredients & Drug Interactions
What is this page for?
First and foremost: checking MicroLactin against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.
Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy
MicroLactin is a dietary supplement by Swanson Ultra with 3 active ingredients. Its ingredients are commonly taken for bone health and osteoporosis prevention, dietary calcium deficiency, heartburn relief (calcium carbonate antacids).Based on those ingredients, 168 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Calcium. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.
Check Your Meds Against MicroLactin by Swanson Ultra
Ask about any prescription or over-the-counter medication and we check it for interactions with MicroLactin by Swanson Ultra — and tell you which ingredient is responsible.
AI summaries are generated from our interaction database for education only — always confirm with your pharmacist. How we use AI
Ask the Pharmacist
A licensed pharmacist will answer your question by email — free, usually within 24 hours.
Got it — thank you!
A licensed pharmacist will answer within 24 hours. Keep an eye on your email (worth checking spam, just in case).
HelloPharmacist Scorecard of MicroLactin by Swanson Ultra
Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.
What’s inside
Full disclosure
MicroLactin contains 2 active ingredients: calcium, which supports bone health and helps your body manage several mineral imbalances, and immunoglobulin G, a milk protein concentrate. The product also includes inactive ingredients — gelatin, stearic acid, calcium palmitate, and microcrystalline cellulose — as the capsule shell and binding agents.
Does it work?
Strong evidence
Calcium in this product is effective for kidney failure, heartburn (dyspepsia), low blood calcium (hypocalcemia), and high potassium in the blood (hyperkalemia), and it's likely effective for osteoporosis. We don't have effectiveness data on file for the immunoglobulin G component.
How safe is it?
Well-documented data
Calcium is generally well tolerated when you take the recommended amount, though high doses can cause problems. The most common side effects from oral calcium are belching, constipation, diarrhea, bloating, and stomach upset.
Rare serious concerns from case reports include kidney stones and calciphylaxis. Some research has raised questions about very high calcium intake (over 1500–2000 mg daily) and prostate cancer risk, as well as a possible link to heart disease at very high levels, though these findings remain debated and often apply to amounts above typical supplement use.
In pregnancy, adequate calcium is important — stay within recommended amounts unless your doctor advises otherwise. Calcium needs can be met during breastfeeding as well; use recommended amounts and check with your provider.
Meds to double-check
Major interaction found
Before taking this product, check whether you use integrase inhibitors for HIV (dolutegravir, elvitegravir), intravenous ceftriaxone (Rocephin), the thyroid drug levothyroxine (Synthroid), the heart drugs sotalol (Betapace) or diltiazem (Cardizem), the HIV drug raltegravir (Isentress), or the skin medication calcipotriene (Dovonex). Calcium can reduce how well these drugs work or how much your body absorbs them.
The bottom line
Scorecard at a glanceFully disclosed formula with clinical evidence supporting its stated purpose. Major medication interactions have been identified, and safety information is well characterized.
MicroLactin is useful if you need to manage bone health, correct low calcium, or treat heartburn or high potassium — but calcium interacts with several important medications, especially HIV drugs, thyroid hormone, and certain antibiotics. If you take any prescription medication, run it through the checker on this page before you start.
Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI
Assessment coverage: 1 of 2 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 25, 2019.
This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed
General information
Key facts about MicroLactin, straight from the product label.
| Brand | Swanson Ultra |
|---|---|
| Barcode (UPC) | 087614022024 |
| Net contents | 120 Capsule(s) |
| Market status | On market |
| Date entered into DSLD | Feb 25, 2019 |
| DSLD ID | 184833 |
| Product type | Other Combinations |
| Supplement form | Capsule |
| Dietary claims / uses | All Other |
| Intended target group(s) | Adult (18 - 50 Years) |
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.
Supplement Facts
The label details for MicroLactin by Swanson Ultra, sourced from the NIH Dietary Supplement Label Database.
Supplement Facts
| Ingredient | Amount | % DV |
|---|---|---|
| Calories | 5 Calorie(s), 2.5 Calorie(s) | -- |
| Protein | 2 Gram(s), 1 Gram(s) | -- |
| Immunoglobulin G | 12 mg, 6 mg | -- |
| Calcium | 44 mg, 22 mg | 3%, 2% |
| MicroLactin Milk Protein Concentrate | 2 Gram(s), 1 Gram(s) | -- |
Other ingredients: Gelatin, Stearic Acid, Calcium Palmitate, Microcrystalline Cellulose
Tap any ingredient to jump to its full detail below.
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
General Statements
The Most Advanced Nutrition Technology Capsules
Servings Per Container 60 (During Maintenance Phase)
To reorder, call toll free 1-800-437-4148 or visit our website at www.swansonvitamins.com
FDA Statement of Identity
Dietary Supplement
Seals/Symbols
Guaranteed purity & potency
Precautions
Do not use if seal is broken.
Keep out of reach of children.
Contains milk.
Storage
Store in a cool, dry place.
Suggested/Recommended/Usage/Directions
Suggested use: As a dietary supplement, take four capsules two times per day with water for the first 10-14 days (loading phase). Take two capsules two times per day with water thereafter for maintenance purposes.
General
SWU202 Rev 1 07 12 17
Formula
Contains milk.
Brand IP Statement(s)
MicroLactin is a registered trademark of Stolle Milk Biologics, Inc. U.S. patent #5,650,175.
Is this label outdated? Report a formula or label change and our pharmacy team will review it.
MicroLactin by Swanson Ultra label
The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.
Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.
View the full label (PDF)The Ingredients in MicroLactin by Swanson Ultra
These are the 3 active ingredients this product is made of. Select any to open its full monograph.
Serving size4 Capsule(s) Dosage formCapsule Servings per container60 Amounts shown are per serving.
Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.
Protein
Calcium
Interacts with168 drugs
Calcium is an essential mineral your body needs for strong bones, nerve signaling, and muscle function, and supplements can help fill gaps when diet f...
Calcium monograph & interactionsMicroLactin Milk Protein Concentrate
- › Immunoglobulin G
Other (inactive) ingredients: Gelatin, Stearic Acid, Calcium Palmitate, Microcrystalline Cellulose. These complete the product’s ingredient list but are not active constituents.
MicroLactin by Swanson Ultra Drug Interactions
HelloPharmacist Interaction Report
MicroLactin by Swanson Ultra contains calcium, which interacts with a number of medications.
The most serious concern is with integrase inhibitors — dolutegravir (Tivicay) and elvitegravir (Vitekta) — where calcium can cut drug levels by 40% or more, potentially reducing their ability to control HIV. You'd need to time doses carefully: take dolutegravir 2 hours before or 6 hours after calcium, and elvitegravir 2 hours before or 2 hours after.
Calcium also poses a Major risk with ceftriaxone (Rocephin) if you receive it intravenously — the two can form dangerous deposits in the lungs and kidneys, so IV calcium must be avoided within 48 hours of IV ceftriaxone.
Read the full breakdown — every affected drug type, severity by severity
Several other drug types are affected at Moderate severity. Calcium reduces how well your body absorbs the thyroid hormone levothyroxine (Synthroid), so separate those doses by at least 4 hours.
It also lowers absorption of the heart drug sotalol (Betapace) — space them by at least 2 hours before or 4–6 hours after calcium. The HIV drug raltegravir (Isentress) and the calcium-regulating topical calcipotriene (Dovonex) may also be affected, and calcium could theoretically reduce the heart drug diltiazem's (Cardizem) effectiveness.
We could not check the other active ingredient, immunoglobulin G, against medications — interaction data is not on file for it. Please use the medication checker on this page to verify your exact prescriptions before you start.
Check your own medications below · Editorial policy · How we use AI
Want to check YOUR meds against MicroLactin?
Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.
Go to the checkerIngredients driving the most interactions
Individual Drug Interactions
The ingredients in MicroLactin interact with 168 drugs. Click any drug to see the details.
1 of the 3 ingredients in MicroLactin interact with drugs. Each result below shows which ingredient is responsible. Calcium
AmlodipineNorliqva
How Amlodipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Amlodipine interactionAmlodipine BenzoateKaterzia
How Amlodipine Benzoate interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Amlodipine Benzoate interactionAmlodipine BesilateIstin
How Amlodipine Besilate interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Amlodipine Besilate interactionAmlodipine BesylateNorvasc
How Amlodipine Besylate interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Amlodipine Besylate interactionAmlodipine Besylate, BenazeprilLotrel
How Amlodipine Besylate, Benazepril interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Amlodipine Besylate, Benazepril interactionAmlodipine, CelecoxibConsensi
How Amlodipine, Celecoxib interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Amlodipine, Celecoxib interactionBepridilVascor
How Bepridil interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Bepridil interactionEnalapril Maleate, FelodipineLexxel
How Enalapril Maleate, Felodipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Enalapril Maleate, Felodipine interactionFelodipinePlendil, Renedil
How Felodipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Felodipine interactionIsradipineDynacirc CR
How Isradipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Isradipine interactionLercanidipine HydrochlorideZanidip
How Lercanidipine Hydrochloride interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Lercanidipine Hydrochloride interactionLevamlodipineConjupri
How Levamlodipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Levamlodipine interactionNicardipineCardene, Cardene IV, Cardene SR
How Nicardipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Nicardipine interactionNifedipineAdalat, Adalat CC, Adalat LA, Adalat PA, Adalat Retard, Adalat XL +15 more
How Nifedipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Nifedipine interactionNisoldipineSular
How Nisoldipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Nisoldipine interactionNitrendipineCardif
How Nitrendipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Nitrendipine interactionPerindopril Arginine, AmlodipinePrestalia
How Perindopril Arginine, Amlodipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Perindopril Arginine, Amlodipine interactionTelmisartan, AmlodipineTwynsta
How Telmisartan, Amlodipine interacts with MicroLactin — through 1 ingredient. Tap an ingredient for the detail:
CalciumCalcium Channel Blockers Minor
Interaction Summary
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Read the full Calcium + Telmisartan, Amlodipine interactionEach ingredient & the kinds of drugs it affects
For each ingredient in MicroLactin with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.
Calcium
Ceftriaxone (Rocephin)
Co-administration of intravenous calcium and ceftriaxone can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys.
Avoid administering intravenous calcium in any form, such as parenteral nutrition or Lactated Ringers, within 48 hours of intravenous ceftriaxone. Case reports in neonates show that administering intravenous ceftriaxone and calcium can result in precipitation of a ceftriaxone-calcium salt in the lungs and kidneys. In several cases, neonates have died as a result of this interaction. So far there are no reports in adults; however, there is still concern that this interaction might occur in adults.
Dolutegravir (Tivicay)
Calcium seems to reduce levels of dolutegravir.
Advise patients to take dolutegravir either 2 hours before or 6 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium carbonate 1200 mg concomitantly with dolutegravir 50 mg reduces plasma levels of dolutegravir by almost 40%. Calcium appears to decrease levels of dolutegravir through chelation.
Elvitegravir (Vitekta)
Calcium seems to reduce levels of elvitegravir.
Advise patients to take elvitegravir either 2 hours before or 2 hours after taking calcium supplements. Pharmacokinetic research suggests that taking calcium along with elvitegravir can reduce blood levels of elvitegravir through chelation.
Aluminum
Calcium citrate might increase aluminum absorption and toxicity. Other types of calcium do not increase aluminum absorption.
Calcium citrate can increase the absorption of aluminum when taken with aluminum hydroxide. The increase in aluminum levels may become toxic, particularly in individuals with kidney disease. However, the effect of calcium citrate on aluminum absorption is due to the citrate anion rather than calcium cation. Calcium acetate does not appear to increase aluminum absorption.
Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy)
Calcium might decrease levels of bictegravir/emtricitabine/tenofovir alafenamide by reducing its absorption when taken in a fasting state.
Advise patients that bictegravir/emtricitabine/tenofovir alafenamide and calcium can be taken together if taken with food. However, if taken on an empty stomach, bictegravir/emtricitabine/tenofovir alafenamide should not be taken with, or 2 hours after, calcium containing products.
Bisphosphonates
Calcium reduces the absorption of bisphosphonates.
Advise patients to take bisphosphonates at least 30 minutes before calcium, but preferably at a different time of day. Calcium supplements decrease absorption of bisphosphonates.
Calcipotriene (Dovonex)
Taking calcipotriene with calcium might increase the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with calcium supplements might increase the risk of hypercalcemia.
Digoxin (Lanoxin)
Using intravenous calcium with digoxin might increase the risk of fatal cardiac arrhythmias.
Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. However, one retrospective analysis of clinical data suggests that intravenous calcium does not increase the risk of dysrhythmias or mortality in patients receiving digoxin.
Diltiazem (Cardizem, Others)
Theoretically, calcium may reduce the therapeutic effects of diltiazem.
Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically, calcium might increase this risk of hypercalcemia and reduce the effectiveness of diltiazem.
Levothyroxine (Synthroid, Others)
Calcium seems to reduce the absorption and effectiveness of levothyroxine.
Advise patients to take levothyroxine and calcium supplements at least 4 hours apart. Calcium reduces levothyroxine absorption, probably by forming insoluble complexes. Calcium carbonate supplements reduce effectiveness of levothyroxine in patients with hypothyroidism.
Lithium
Theoretically, concomitant use of calcium and lithium may increase this risk of hypercalcemia.
Clinical research suggests that long-term use of lithium may cause hypercalcemia in 10% to 60% of patients. Theoretically, concomitant use of lithium and calcium supplements may further increase this risk.
Quinolone Antibiotics
Calcium seems to reduce the absorption of quinolone antibiotics.
Advise patients to take oral quinolones at least 2 hours before or 4-6 hours after calcium supplements or calcium-fortified foods. Taking calcium at the same time as oral quinolones can reduce quinolone absorption. Calcium binds to quinolones in the gut.
Raltegravir (Isentress)
Calcium may reduce levels of raltegravir.
Pharmacokinetic research shows that taking a single dose of calcium carbonate 3000 mg along with raltegravir 400 mg twice daily modestly decreases the mean area under the curve of raltegravir, but the decrease does not necessitate a dose adjustment of raltegravir. However, a case of elevated HIV-1 RNA levels and documented resistance to raltegravir has been reported for a patient taking calcium carbonate 1 gram three times daily plus vitamin D3 (cholecalciferol) 400 IU three times daily in combination with raltegravir 400 mg twice daily for 11 months. It is thought that calcium reduced raltegravir levels by chelation, leading to treatment failure.
Sotalol (Betapace)
Calcium seems to reduce the absorption of sotalol.
Advise patients to separate doses by at least 2 hours before or 4-6 hours after calcium. Calcium appears to reduce the absorption of sotalol, probably by forming insoluble complexes.
Tetracycline Antibiotics
Calcium seems to reduce the absorption of tetracycline antibiotics.
Advise patients to take oral tetracyclines at least 2 hours before, or 4-6 hours after calcium supplements. Taking calcium at the same time as oral tetracyclines can reduce tetracycline absorption. Calcium binds to tetracyclines in the gut.
Thiazide Diuretics
Taking calcium along with thiazides might increase the risk of hypercalcemia and renal failure.
Thiazides reduce calcium excretion by the kidneys. Using thiazides along with moderately large amounts of calcium carbonate increases the risk of milk-alkali syndrome (hypercalcemia, metabolic alkalosis, renal failure). Patients may need to have their serum calcium levels and/or parathyroid function monitored regularly.
Verapamil (Calan, Others)
Theoretically, calcium may reduce the therapeutic effects of verapamil.
Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically, use of calcium supplements may increase this risk of hypercalcemia and reduce the effectiveness of verapamil.
Calcium Channel Blockers
Intravenous calcium may decrease the effects of calcium channel blockers; oral calcium is unlikely to have this effect.
Intravenous calcium is used to decrease the effects of calcium channel blockers in the management of overdose. Intravenous calcium gluconate has been used before intravenous verapamil (Isoptin) to prevent or reduce the hypotensive effects without affecting the antiarrhythmic effects. But there is no evidence that dietary or supplemental calcium when taken orally interacts with calcium channel blockers.
Brand information
Manufacturer and brand details for MicroLactin, from the product label.
Swanson Ultra
See all Swanson Ultra products- Name
- Swanson Health Products
- City
- Fargo
- State
- ND
- ZipCode
- 58104
- Phone Number
- 1-800-437-4148
- Web Address
- www.swansonvitamins.com
MicroLactin by Swanson Ultra: Common Questions
Does MicroLactin by Swanson Ultra interact with any medications?
How can one product interact with so many drugs?
Where does this information come from?
What is immunoglobulin G, and why is it in this product?
Can I take this product if I'm pregnant or breastfeeding?
What are the most common side effects?
How far apart should I take this if I'm on levothyroxine?
Is this product safe to use long-term?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Not sure if MicroLactin is safe with your meds?
Our pharmacists answer your medication & supplement questions — free.
Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.
The Full Monographs Behind MicroLactin’s Ingredients
Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.
Sources & How We Checked
MicroLactin's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.
- NIH Dietary Supplement Label Database (DSLD) — The official product label on file for this supplement.
- Natural Medicines (Therapeutic Research Center) — Evidence-graded clinical reference behind the ingredient interaction data.
Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.
The 62 references behind this product’s interaction data
Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.
Calcium 62 references
- Shils M, Olson A, Shike M. Modern Nutrition in Health and Disease. 8th ed. Philadelphia, PA: Lea and Febiger, 1994.
- Hernandez-Avila M, Gonzalez-Cossio T, Hernandez-Avila JE, et al. Dietary calcium supplements to lower blood lead levels in lactating women: a randomized placebo-controlled trial. Epidemiology 2003;14:206-12.. PubMed
- Thys-Jacobs S, Ceccarelli S, Bierman A, et al. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. J Gen Intern Med 1989;4:183-9. PubMed
- Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999;57:855-70.
- Clemens JD, Feinstein AR. Calcium carbonate and constipation: a historical review of medical mythopoeia. Gastroenterology 1977;72:957-61. DOI
- Saunders D, Sillery J, Chapman R. Effect of calcium carbonate and aluminum hydroxide on human intestinal function. Dig Dis Sci 1988;33:409-13. PubMed
- Friedman PA, Bushinsky DA. Diuretic effects on calcium metabolism. Semin Nephrol 1999;19:551-6.
- Koo WK, Walters JC, Esterlitz J, et al. Maternal calcium supplementation and fetal bone mineralization. Obstet Gynecol 1999;94:577-82. DOI
- Raman L, Rajalakshmi K, Krishnamachari KAVR, et al. Effect of calcium supplementation to undernourished mothers during pregnancy on the bone density of the neonates. Am J Clin Nutr 1978; 31:466-9. DOI
- Murry JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietician. J Am Diet Assoc 1991;91:66-73.
- Chan JM, Giovannucci E, Andersson SO, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer. Cancer Causes Control 1998;9:559-66.
- Butner LE, Fulco PP, Feldman G, et al. Calcium carbonate-induced hypothyroidism. Ann Intern Med 2000:132:595. PubMed
- Schneyer CR. Calcium carbonate and reduction of levothyroxine efficacy. JAMA 1998;279:750. PubMed
- Moser LR, Smythe MA, Tisdale JE. The use of calcium salts in the prevention and management of verapamil-induced hypotension. Ann Pharmacother 2000;34:622-9. PubMed
- Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000;283:2822-5. PubMed
- Kahela P, Anttila M, Tikkanen R, Sundquist H. Effect of food, food constituents and fluid volume on the bioavailability of sotalol. Acta Pharmacol Toxicol (Copenh) 1979;44:7-12.. PubMed
- Pletz MW, Petzold P, Allen A, et al. Effect of calcium carbonate on bioavailability of orally administered gemifloxacin. Antimicrob Agents Chemother 2003;47:2158-60.. PubMed
- Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
- Decktor DL, Robinson M, Maton PN, et al. Effects of aluminum/magnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn. Am J Ther 1995;2:546-52. PubMed
- Simoneau G. Absence of rebound effect with calcium carbonate. Eur J Drug Metab Pharmacokinet 1996;21:351-7. PubMed
- Peters ML, Leonard M, Licata AA. Role of alendronate and risedronate in preventing and treating osteoporosis. Cleve Clin J Med 2001;68:945-51. PubMed
- Bourke JF, Mumford R, Whittaker P, et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997;37:929-34.
- Gueguen L, Pointillart A. The bioavailability of dietary calcium. J Am Coll Nutr 2000;19:119s-136s. PubMed
- Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J 1999;75:554-6. PubMed
- Bania TC, Blaufeux B, Hughes S, et al. Calcium and digoxin vs. calcium alone for severe verapamil toxicity. Acad Emerg Med 2000;7:1089-96. PubMed
- Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 2005;81:1147-54. PubMed
- Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2004;(1):CD003548. PubMed
- Tavani A, Bertuccio P, Bosetti C, et al. Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 2005;48:27-33. PubMed
- Giovannucci E, Liu Y, Stampfer MJ, Willett WC. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:203-10. PubMed
- Rocephin (ceftriaxone) and calcium interaction. Pharmacist's Letter / Prescriber's Letter 2007;23(10):231005.
- Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised control trial. BMJ 2008;336:262-6.
- Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691. PubMed
- Calcium supplementation and vascular events. Pharmacist's Letter / Prescriber's Letter 2008;24(3):240306.
- Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
- Coburn JW, Mischel MG, Goodman WG, et al. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis. 1991;17(6):708-11. PubMed
- Bradley JS, Wassel RT, Lee L, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609-13. PubMed
- Kays MB, Overholser BR, Mueller BA, et al. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003;42(6):1253-9. PubMed
- Neuhofel, A. L., Wilton, J. H., Victory, J. M., Hejmanowsk, L. G., and Amsden, G. W. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol. 2002;42(4):461-466. DOI
- Dickinson, H. O., Nicolson, D. J., Cook, J. V., Campbell, F., Beyer, F. R., Ford, G. A., and Mason, J. Calcium supplementation for the management of primary hypertension in adults. Cochrane.Database.Syst.Rev. 2006;(2):CD004639. PubMed
- Jones, B. J. and Twomey, P. J. Requesting patterns for serum calcium concentration in patients on long-term lithium therapy. Int J Clin Pract. 2009;63(1):170-172. PubMed
- Levine, M., Nikkanen, H., and Pallin, D. J. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg.Med. 2011;40(1):41-46. PubMed
- Castelo-Branco, C., Ciria-Recasens, M., Cancelo-Hidalgo, M. J., Palacios, S., Haya-Palazuelos, J., Carbonell-Abello, J., Blanch-Rubio, J., Martinez-Zapata, M. J., Manasanch, J., and Perez-Edo, L. Efficacy of ossein-hydroxyapatite complex compared with ca
- Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation i
- Chung M, Tang AM, Fu Z. Calcium Intake and Cardiovascular Disease Risk: An Updated Systematic Review and Meta-analysis. Ann Intern Med. 2016 Oct 25. PubMed
- Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. 1990;38(5):937-41. PubMed
- Lewis JR, Radavelli-Bagatini S, Rejnmark L, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J Bone Miner Res PubMed
- Jalloh MA, Gregory PJ, Hein D, et al. Dietary supplement interactions with antiretrovirals: a systematic review. Int J STD AIDS. 2017 Jan;28(1):4-15. PubMed
- Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
- Grove ML, Cook D. Calcium and heart attacks. Doesn't apply to most calcium prescriptions. BMJ. 2010;341:c5003. PubMed
- Insentress [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2014.
- Roberts JL, Kiser JJ, Hindman JT, Meditz AL. Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration. Pharmacotherapy 2011;31(10):298e-302e. DOI
- Vitekta [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2014.
- Storan ER, O'Gorman SM, Murphy A, Laing M. Case Report of Calciphylaxis Secondary to Calcium and Vitamin D<sub>3</sub> Supplementation. J Cutan Med Surg. 2017;21(2):162-163. DOI
- Jenkins DJA, Spence JD, Giovannucci EL, et al. Supplemental vitamins and minerals for CVD prevention and treatment. J Am Coll Cardiol 2018;71(22):2570-84. PubMed
- Borkenhagen JF, Connor EL, Stafstrom CE. Neonatal hypocalcemic seizures due to excessive maternal calcium ingestion. Pediatr Neurol 2013;48(6):469-71. PubMed
- WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016 (http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/ anc-positive-pregnancy-experience/en/).
- Aune D, Navarro Rosenblatt DA, Chan DS, et al. Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies. Am J Clin Nutr. 2015;101(1):87-117. PubMed
- Lan T, Park Y, Colditz GA, et al. Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2020;31(10):891-904. PubMed
- Zhang Y, Li Y, Liu J, et al. Association of Vitamin D or Calcium Supplementation with Cardiovascular Outcomes and Mortality: A Meta-Analysis with Trial Sequential Analysis. J Nutr Health Aging 2021;25(2):263-270. PubMed
- Myung SK, Kim HB, Lee YJ, Choi YJ, Oh SW. Calcium Supplements and Risk of Cardiovascular Disease: A Meta-Analysis of Clinical Trials. Nutrients 2021;13(2):368. PubMed
- Hetaimish B. Neonatal Calcinosis Cutis After Treatment of Hypocalcemia with Calcium Gluconate: A Report of 2 Cases. Am J Case Rep 2024;25:e943397. PubMed
- US Food and Drug Administration (FDA). Biktarvy Prescribing Information. October 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210251Orig1s020lbl.pdf. Accessed July 16, 2025.
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC